Phase II trial of pegylated liposomal doxorubicin as consolidation chemotherapy in patients with stage III or IV ovarian or primary peritoneil carcinoma.

被引：0
|
作者：
Disilvestro, PA
Fisher, M
Pearl, M
Valea, F
Buhl, A
Chalas, E
机构：
[1] Women & Infants Hosp Rhode Isl, Providence, RI USA
[2] SUNY Stony Brook, Stony Brook, NY 11794 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5112
引用
收藏
页码：477S / 477S
页数：1
相关论文
共 50 条
  • [1] Phase II trial of liposomal doxorubicin (caelix) in relapses of cisplatin refractory ovarian carcinoma.
    Cervantes, A
    Garcia, T
    de Dueñas, EM
    Insa, A
    de Paz, L
    Lluch, A
    Esgrig, V
    Garcia-Conde, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S86 - S86
  • [2] Non-pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: A multicentric phase II trial
    Brucker, Janina
    Mayer, Christine
    Gebauer, Gerhard
    Mallmann, Peter
    Belau, Antje Kristina
    Schneeweiss, Andreas
    Sohn, Christof
    Eichbaum, Michael
    ONCOLOGY LETTERS, 2016, 12 (02) : 1211 - 1215
  • [3] Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
    Ferrandina, Gabriella
    Ludovisi, Manuela
    Lorusso, Domenica
    Pignata, Sandro
    Breda, Enrico
    Savarese, Antonella
    Del Medico, Pietro
    Scaltriti, Laura
    Katsaros, Dionyssios
    Priolo, Domenico
    Scambia, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) : 890 - 896
  • [4] Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A Multicenter Phase II Trial
    Joly, Florence
    Sevin, Emmanuel
    Lortholary, Alain
    Priou, Frank
    Paitel, J. F.
    Fabbro, Michel
    Henry-Amar, Michel
    Hamond, Karim
    Bourgeois, Hugues
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 312 - 316
  • [5] Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer:: results of a multicenter phase-II trial
    Sehouli, J
    Oskay-Özcelik, G
    Kühne, J
    Stengel, D
    Hindenburg, HJ
    Klare, P
    Heinrich, G
    Schmalfeldt, B
    Mertens, H
    Camara, O
    Lichtenegger, W
    ANNALS OF ONCOLOGY, 2006, 17 (06) : 957 - 961
  • [6] Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
    Mutch, David G.
    Orlando, Mauro
    Goss, Tiana
    Teneriello, Michael G.
    Gordon, Alan N.
    McMeekin, Scott D.
    Wang, Yanping
    Scribner, Dennis R., Jr.
    Marciniack, Martin
    Naumann, R. Wendel
    Secord, Angeles Alvarez
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) : 2811 - 2818
  • [7] Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
    Gordon, AN
    Fleagle, JT
    Guthrie, D
    Parkin, DE
    Gore, ME
    Lacave, AJ
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) : 3312 - 3322
  • [8] A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma
    Ruey-Long Hong
    Yun-Long Tseng
    Cancer Chemotherapy and Pharmacology, 2003, 51 : 433 - 438
  • [9] A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma
    Hong, RL
    Tseng, YL
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (05) : 433 - 438
  • [10] Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
    Pujade-Lauraine, E.
    Fujiwara, K.
    Ledermann, J. A.
    Oza, A. M.
    Kristeleit, R. S.
    Ray-Coquard, I. L.
    Richardson, G. E.
    Sessa, C.
    Yonemori, K.
    Banerjee, S.
    Leary, A.
    Tinker, A. V.
    Jung, K. H.
    Madry, R.
    Park, S. Y.
    Anderson, C. K.
    Zohren, F.
    Stewart, R.
    Wei, C.
    Dychter, S. S.
    Monk, B. J.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 21 - 22
12345